Soehnlein O, Libby P. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589–610.
Article
CAS
Google Scholar
Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ Res. 2021;128(11):1728–46.
Article
CAS
Google Scholar
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, Group CT. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28.
Article
CAS
Google Scholar
Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–9.
Article
CAS
Google Scholar
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT05021835, ZEUS - a research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation (ZEUS); August 26, 2021 [cited June 25, 2022]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT05021835.
Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, Finan C, Hingorani AD, Howson JMM, Burgess S, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.
Article
Google Scholar
Georgakis MK, Gill D. Mendelian randomization studies in stroke: exploration of risk factors and drug targets with human genetic data. Stroke. 2021;52(9):2992–3003.
Article
Google Scholar
Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614–21.
Article
Google Scholar
Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M. Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a Mendelian randomization study. Circ Genom Precis Med. 2020;13(3):e002872.
Article
Google Scholar
Georgakis MK, Malik R, Li X, Gill D, Levin MG, Vy HMT, Judy R, Ritchie M, Verma SS, Regeneron Genetics C, et al. Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association study. Circulation. 2021;143(11):1177–80.
Article
CAS
Google Scholar
Georgakis MK, Malik R, Burgess S, Dichgans M. Additive effects of genetic IL-6 signaling downregulation and LDL-cholesterol lowering on cardiovascular disease: a 2x2 factorial Mendelian randomization analysis. J Am Heart Assoc. 2021; in press.
Georgakis MK, Malik R, Burgess S, Dichgans M. Additive effects of genetic interleukin-6 signaling downregulation and low-density lipoprotein cholesterol lowering on cardiovascular disease: a 2x2 factorial Mendelian randomization analysis. J Am Heart Assoc. 2022;11(1):e023277.
Article
Google Scholar
Ligthart S, Vaez A, Vosa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi E, Rose LM, et al. Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders. Am J Hum Genet. 2018;103(5):691–706.
Article
CAS
Google Scholar
Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars NJ, Aguirre M, Venkataraman GR, Wainberg M, Ollila HM, Pirruccello JP, Qian J et al: Genetics of 38 blood and urine biomarkers in the UK Biobank. bioRxiv 2019:660506. https://doi.org/10.1101/660506.
Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40(7):597–608.
Article
Google Scholar
Quintana RA, Taylor WR. Cellular mechanisms of aortic aneurysm formation. Circ Res. 2019;124(4):607–18.
Article
CAS
Google Scholar
Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333–55.
Article
Google Scholar
Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol. 2013;42(4):1134–44.
Article
Google Scholar
Coscia C, Gill D, Benitez R, Perez T, Malats N, Burgess S. Avoiding collider bias in Mendelian randomization when performing stratified analyses. Eur J Epidemiol. 2022. https://doi.org/10.1007/s10654-022-00879-0.
Staley JR, Burgess S. Semiparametric methods for estimation of a nonlinear exposure-outcome relationship using instrumental variables with application to Mendelian randomization. Genet Epidemiol. 2017;41(4):341–52.
Article
Google Scholar
Levin MG, Klarin D, Georgakis MK, Lynch J, Liao KP, Voight BF, O’Donnell CJ, Chang KM, Assimes TL, Tsao PS, et al. A missense variant in the IL-6 receptor and protection from peripheral artery disease. Circ Res. 2021;129(10):968–70.
Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–56.
Article
CAS
Google Scholar
Papadopoulos A, Palaiopanos K, Bjorkbacka H, Peters A, de Lemos JA, Seshadri S, Dichgans M, Georgakis MK. Circulating interleukin-6 levels and incident ischemic stroke: a systematic review and meta-analysis of prospective studies. Neurology. 2022;98(10):e1002–12.
Article
CAS
Google Scholar
Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–89.
Article
CAS
Google Scholar
Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.
Article
Google Scholar
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, Faggioni R, Luini W, van Hinsbergh V, Sozzani S, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6(3):315–25.
Article
CAS
Google Scholar
Alsaffar H, Martino N, Garrett JP, Adam AP. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am J Physiol Cell Physiol. 2018;314(5):C589–602.
Article
CAS
Google Scholar
Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y, Kano S. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991;260(5 Pt 2):H1713–1717.
CAS
PubMed
Google Scholar
Hegazy SH, Thomassen JQ, Rasmussen IJ, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-Schmidt R. C-reactive protein levels and risk of dementia-observational and genetic studies of 111,242 individuals from the general population. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12568.